Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease
New data showed that empagliflozin reduced the risk of cardiovascular death compared with placebo when added to standard of care in adults with type 2 diabetes and peripheral artery disease. These results, from a post-hoc analysis of the landmark EMPA-REG OUTCOME® trial, were shared as an oral presentation on behalf of Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) at the American Heart Association (AHA) Scientific Sessions 2017 in Anaheim, Calif. and simultaneously published online in the AHA’s journal Circulation.1
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171114005733/en/
“Peripheral artery disease, one of the most common cardiovascular complications associated with type 2 diabetes, increases the risk of death from cardiovascular causes,” said Subodh Verma, M.D., cardiac surgeon-scientist at St. Michael’s Hospital and professor at the University of Toronto. “There is an urgent need for treatment options that can improve cardiovascular-related outcomes in people with type 2 diabetes and peripheral artery disease.”
Approximately one in three people with diabetes over the age of 50 have peripheral artery disease, a narrowing of the arteries outside the heart, usually those leading to the arms, legs and feet, due to a buildup of fatty deposits.2 Peripheral artery disease can be life-threatening when blockages restrict circulation causing damage to limbs and can also be associated with damage to vital organs such as the heart, kidneys and brain.3 If peripheral artery disease is not managed properly, it can also lead to amputation, which may result in hospitalization, disability and death.4
At study start, 21 percent of the more than 7,000 EMPA-REG OUTCOME® trial participants had existing peripheral artery disease. The analysis in this patient population showed that compared with placebo, on top of standard of care:
- Empagliflozin reduced the risk of cardiovascular death by 43 percent
- Death from any cause was reduced by 38 percent and hospitalisation for heart failure by 44 percent
- Risk for the composite endpoint of cardiovascular death, non-fatal heart attack or non-fatal stroke was reduced by 16 percent
- New or worsening kidney disease, known as nephropathy, was reduced by 46 percent
- Overall, the cardiovascular and renal effects observed in patients with peripheral artery disease were consistent with previously reported results of the overall trial population in EMPA-REG OUTCOME®
Overall side effects and serious side effects were balanced between the empagliflozin and placebo groups in adults with and without peripheral artery disease. In the group with peripheral artery disease, lower-limb amputations occurred in 5.5 percent of those treated with empagliflozin and 6.3 percent of those treated with placebo. In the group without peripheral artery disease, lower-limb amputations occurred in 0.9 percent of those treated with empagliflozin and 0.7 percent of those treated with placebo.
“Through ongoing sub-analyses of the EMPA-REG OUTCOME® data, we are gaining a better understanding of how empagliflozin may help a wide range of people living with type 2 diabetes and its complications,” said Dr Georg van Husen, Corporate Senior Vice President, Head of the Therapeutic Area CardioMetabolism, Boehringer Ingelheim. “The data presented and published at the AHA Scientific Sessions showed that empagliflozin reduced the risk for cardiovascular death and kidney disease in this highly vulnerable population of people with type 2 diabetes and peripheral artery disease.”
About Diabetes and Cardiovascular Disease
More than 415 million people worldwide have diabetes, of which 193 million are estimated to be undiagnosed.5 By 2040, the number of people with diabetes is expected to rise to 642 million people worldwide.5 T2D is the most common form of diabetes, responsible for up to 91 percent of diabetes cases in high-income countries.5 Diabetes is a chronic condition that occurs when the body either does not properly produce, or use, the hormone insulin.5
Due to the complications associated with diabetes, such as high blood sugar, high blood pressure and obesity, CV disease is a major complication and the leading cause of death associated with diabetes.6,7 People with diabetes are two to four times more likely to develop CV disease than people without diabetes.7 In 2015, diabetes caused 5 million deaths worldwide, with CV disease as the leading cause.5,7 Approximately 50 percent of deaths in people with T2D worldwide are caused by CV disease.8,9
Having a history of diabetes at age 60 can shorten a person’s lifespan by as much as six years compared with someone without diabetes. And having both diabetes and a history of heart attack or stroke at age 60 can shorten a person’s lifespan by as much as 12 years compared with someone without these conditions.10
Empagliflozin (marketed as Jardiance®) is an oral, once daily, highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor approved for use in Europe, the United States and other markets around the world for the treatment of adults with type 2 diabetes.
Inhibition of SGLT2 with empagliflozin in people with type 2 diabetes and high blood sugar levels leads to excretion of excess sugar in the urine. In addition, initiation of empagliflozin increases excretion of salt from the body (i.e. sodium) and reduces the fluid load of the body’s blood vessel system (i.e. intravascular volume). The glucosuria, natriuresis and osmotic diuresis observed with empagliflozin may contribute to the improvement in cardiovascular outcomes.11
Empagliflozin is not for people with type 1 diabetes or for people with diabetic ketoacidosis (increased ketones in the blood or urine).
About EMPA-REG OUTCOME ®12
EMPA-REG OUTCOME® was a long-term, multicentre, randomised, double-blind, placebo-controlled trial of more than 7,000 people from 42 countries with type 2 diabetes at high risk for cardiovascular events.
The study assessed the effect of empagliflozin (10 mg or 25 mg once daily) added to standard of care compared with placebo added to standard of care. Standard of care was comprised of glucose-lowering agents and cardiovascular drugs (including for blood pressure and cholesterol). The primary endpoint was defined as time to first occurrence of cardiovascular death, non-fatal heart attack or non-fatal stroke.
Over a median of 3.1 years, empagliflozin significantly reduced the risk of CV death, non-fatal heart attack or non-fatal stroke by 14 percent versus placebo. The risk of CV death was reduced by 38 percent, with no significant difference in the risk of non-fatal heart attack or non-fatal stroke. The overall safety profile of empagliflozin was consistent with that of previous trials.
Please click on the following link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/AHA-2017-Empagliflozin.
Dr Petra Kienle
Product Communication Manager
Phone: +49 (6132) 77 143877
Phone: +1 (317) 478 5423
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
SpinalCyte Announces Sustained 12-Month MRI Outcomes After CybroCell™ Injection14.11.2018 23:07 | Tiedote
SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc nucleus using its universal donor product, CybroCell™, today announced that a single injection of modified human dermal fibroblasts (HDFs), resulted in significant improvements of disc height and pain reduction 12 months after injection of the cell therapy for patients with degenerative disc disease (DDD). The trial assessed patients using the Oswestry Disability Index (ODI), Visual Analogue Scale (VAS) and disc height via MRI scans. Using composite scoring, 54% of the treatment arm patients met all three endpoints as compared to only 17% with the placebo (p=0.0003). Over 84% of patients in the treatment group of CybroCell™ or CybroCell™ with platelet rich plasma (PRP) injections had an increase or no change in disc height compared to 25% for the placebo saline injection. Analyzed individually, 83% of spinal discs that were injected with CybroCell™ had an increase or no change in disc he
Raising Awareness about Early Onset Dementia: “Don’t Leave me now”, Written by Brian Daniels14.11.2018 19:55 | Tiedote
The Fondation IPSEN is delighted to invite you to a theatre performance about familial upheavals when a family member is affected by Alzheimer’s disease or cerebral dementia (November 21 st at 4pm). This play has been written by playwright Brian Daniels and directed by Jeni Draper, has had more than 200 performances and explores with insight and humour the impact of early onset dementia on family life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005695/en/ (Graphic: Business Wire) Free entrance, but registration is mandatory (limited seats): Please click here NOVEMBER 21 st , 4 pm “Le Petit Théâtre de la Fondation IPSEN” 65 quai George Gorse 92150 Boulogne-Billancourt (Metro Line 9, Pont-de-Sèvres) About the Project Our “Science for People” program is composed of accessible meetings and webinars to improve access to science. Brian Daniels’ play “Don’t leave me now” is about caregivers of people with Alzheimer’s Dise
HCL Technologies Celebrates 10 Years of Success in the Nordics14.11.2018 19:44 | Tiedote
HCL Technologies (HCL), a leading global technology company, is celebrating its 10-year anniversary in the Nordic region. During this time, the company has achieved significant successes, which have seen the Nordics grow to become HCL’s largest market in Europe. Today, HCL employs more than 1,600 people in the Nordics representing 31 nationalities, with 55 large-scale transformational clients including four out of the six Fortune Global 500 companies in the region. While several significant milestones have been successfully achieved, HCL looks forward to the future and is dedicated to helping its clients in the Nordics to drive innovation and growth. The celebration coincides with a series of initiatives to mark this occasion starting with the opening of a new office at HCL’s Nordics headquarters in Central Stockholm. “We are humbled by the success that we have achieved together with our clients, colleagues and partners in the Nordics,” said Pankaj Tagra, EVP Nordic and DACH Head, HCL
The Next Industrial Transformation is Here: Rockwell Automation is Helping Businesses Prepare to Succeed at Automation Fair 201814.11.2018 19:35 | Tiedote
Today, at its annual Automation Fair, Rockwell Automation unveiled its new brand promise: Expanding Human Possibility by combining the imaginations of people with the intelligence of machines. The brand promise supports the company’s emphasis on bringing The Connected Enterprise to life and how, by linking people, machines and data across an entire business, manufacturers become more effective and productive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005671/en/ Blake Moret, chairman and CEO, Rockwell Automation, shares his vision for bringing the Connected Enterprise to life and how manufacturers can expand human possibility by linking people, machines and data across their businesses, helping them to become more effective and productive. (Photo: Business Wire) “The new Rockwell Automation brand emphasizes the central role that people play in advanced manufacturing and underscores our focus on ways we maximize per
Hospital in Cox’s Bazar Will Offer 24/7 Medical Aid to 140,000 Rohingya Refugees14.11.2018 18:53 | Tiedote
A 100-bed capacity hospital opened in Cox’s Bazar district in Bangladesh. It is expected to serve 140,000 Rohingya refugees based in the Kutupalong camp. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005631/en/ Sheikh Sultan bin Ahmed Al Qasimi, humanitarian envoy of the foundation and chairman of SMC inaugurated the hospital last Friday. (Photo: Business Wire) This round-the-clock medical facility, built and managed by Médecins Sans Frontières (MSF) – Doctors without Borders with the support of Sharjah-based international humanitarian organisation, The Big Heart Foundation (TBHF), aims to treat 7,200 people in its first year. Part of TBHF’s leading humanitarian efforts to reach out globally to vulnerable communities, this hospital project was supported by AED 3 million donation from Sharjah Media Corporation (SMC), through its public fundraising initiative on healthcare projects, and will offer much-needed relief to
Janssen Seeks Expanded Use of IMBRUVICA®▼ (ibrutinib) in Two Indications in Europe14.11.2018 17:23 | Tiedote
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of two Type II variation applications to the European Medicines Agency (EMA) seeking approval for the expanded use of IMBRUVICA® (ibrutinib). One application seeks to include use of ibrutinib in combination with obinutuzumab in previously untreated adults with chronic lymphocytic leukaemia (CLL) and to add long-term follow-up data from the existing label studies RESONATETM (PCYC-1112) and RESONATETM-2 (PCYC-1115). The second is for use of ibrutinib plus rituximab for the treatment of previously untreated and relapsed/refractory adults with Waldenström's macroglobulinemia (WM). “Today’s news brings us one step closer to potentially offering ibrutinib in new combinations for patients where unmet needs still persist,” said Dr. Catherine Taylor, Haematology Therapy Area Lead, Europe, Middle East and Africa (EMEA), Janssen-Cilag Limited. “Ibrutinib continues to demonstrate clinical benefit over the long
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme